Surendra Dasari, Michael R McCarthy, Antonina A Wojcik, Beth A Pitel, Arpan Samaddar, Burak Tekin, Rumeal D Whaley, Aditya Raghunathan, Loren Herrera Hernandez, Rafael E Jimenez, Brad J Stish, R Houston Thompson, Bradley C Leibovich, Stephen A Boorjian, R Jeffrey Karnes, Daniel S Childs, J Fernando Quevedo, Eugene D Kwon, Lance C Pagliaro, Brian A Costello, Kevin C Halling, John C Cheville, Benjamin R Kipp, Sounak Gupta
Primary prostatic adenocarcinoma (pPC) undergoes genomic evolution secondary to therapy-related selection pressures as it transitions to metastatic noncastrate (mNC-PC) and castrate resistant (mCR-PC) disease. Next generation sequencing results were evaluated for pPC (n = 97), locally advanced disease (involving urinary bladder/rectum, n = 12), mNC-PC (n = 21), and mCR-PC (n = 54). We identified enrichment of TP53 alterations in high-grade pPC, TP53/RB1 alterations in HGNE disease, and AR alterations in metastatic and castrate resistant disease...
February 27, 2024: Prostate Cancer and Prostatic Diseases